Evidence map›Paper›PMID 42699530›Full record

ArticleAsian journal of pharmaceutical sciences2026

Injectable dual-affinity self-assembling peptide hydrogels for local controlled delivery of therapeutic antibodies.

Weiping Cui, Limin Zhang, Chang Yang, Bing He, Hua Zhang, Xueqing Wang, Zhiwen Zhang, Qiang Zhang, Wenbing Dai

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Asian journal of pharmaceutical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Weiping CuiBeijing Key Laboratory of Advanced Pharmaceutical Preparation, State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China.
Limin ZhangBeijing Key Laboratory of Advanced Pharmaceutical Preparation, State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China.
Chang YangBeijing Key Laboratory of Advanced Pharmaceutical Preparation, State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China.
Bing HeBeijing Key Laboratory of Advanced Pharmaceutical Preparation, State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China.
Hua ZhangBeijing Key Laboratory of Advanced Pharmaceutical Preparation, State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China.
Xueqing WangBeijing Key Laboratory of Advanced Pharmaceutical Preparation, State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China.
Zhiwen ZhangSchool of Pharmacy, Key laboratory of smart drug delivery (Ministry of Education) & National key laboratory of complex drug formulations for overcoming delivery barriers, Fudan University, Shanghai 201203, China.
Qiang ZhangBeijing Key Laboratory of Advanced Pharmaceutical Preparation, State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China.
Wenbing DaiBeijing Key Laboratory of Advanced Pharmaceutical Preparation, State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Therapeutic monoclonal antibodies have revolutionized the treatment of cancers, infectious diseases and immune disorders; however, their efficacy is compromised by limitations associated with systemic administration, including systemic toxicity, poor patient compliance and inadequate drug concentration at pathological sites. Hydrogels are promising carriers for localized antibody delivery, but conventional formulations fail to simultaneously address the dual challenges of uncontrolled antibody release and insufficient hydrogel retention at the target site. Herein, leveraging a peptide co-assembly strategy, we engineered an injectable dual-affinity self-assembling peptide hydrogel for localized antibody delivery. This hydrogel integrates three components: peptide FEK as the hydrogel matrix, MEP-FEK incorporating 4-mercaptoethylpyridine (MEP) for non-covalent antibody binding, and C

Indexed as

Co-assembled peptideCollagen type I-binding peptideDual-affinity hydrogelLocal antibody deliveryPeptide hydrogelTrastuzumab

Identifiers

PMID42699530
PMCPMC13543808

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.